VJHemOnc is committed to improving our service to you

SOHO Italy 2020 | Multiple myeloma: ADCs and BiTEs

VJHemOnc is committed to improving our service to you

Hans Lee

Hans Lee, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the current role of antibody-drug conjugates (ADCs) and bi-specific antibodies in multiple myeloma, including belantamab mafodotin, an antibody-drug conjugate, recently approved in the U.S by the FDA for the treatment of relapsed/refractory multiple myeloma and highlights the ocular toxicities associated with this therapy. Dr Lee also discusses bi-specific antibodies as an exciting, off-the-shelf approach to the treatment of multiple myeloma, including the BiTE, AMG-420, CC-93269, and teclistamab. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter